Skip to main content
. 2022 Nov 14;25(2):545–555. doi: 10.1111/dom.14898

TABLE 3.

Safety

Incidence, n (%) Gla‐300 (N = 172) IDeg‐100 (N = 171)
Any TEAE 50 (29.1) 35 (20.5)
Any treatment‐emergent SAE 7 (4.1) 8 (4.7)
Any TEAE leading to death 0 0
Any TEAE leading to permanent treatment discontinuation 0 0
Any treatment‐related TEAE 4 (2.3) 7 (4.1)

Abbreviations: Gla‐300, insulin glargine 300 U/ml; IDeg‐100, insulin degludec 100 U/ml; SAE, serious adverse event; TEAE, treatment‐emergent adverse event.